Literature DB >> 156364

Inhibitory spectrum of alpha 2-plasmin inhibitor.

H Saito, G H Goldsmith, M Moroi, N Aoki.   

Abstract

alpha 2-Plasmin inhibitor (alpha 2PI) has been recently characterized as a fast-reacting inhibitor of plasmin in human plasma and appears to play an important role in the regulation of fibrinolysis in vivo. We have studied the effect of purified alpha 2PI upon various proteases participating in human blood coagulation and kinin generation. At physiological concentration (50 microgram/ml), alpha 2PI inhibited the clot-promoting and prekallikrein-activating activity of Hageman factor fragments, the amidolytic, kininogenase, and clot-promoting activities of plasma kallikrein, and the clot-promoting properties of activated plasma thromboplastin antecedent (PTA, Factor XIa) and thrombin. alpha 2PI had minimal inhibitory effect on surface-bound activated PTA and activated Stuart factor (Factor Xa). alpha 2PI did not inhibit the activity of activated Christmas factor (Factor IXa) or urinary kallikrein. Heparin (1.5-2.0 units/ml) did not enhance the inhibitory function of alpha 2PI. These results suggest that, like other plasma protease inhibitors, alpha 2PI possesses a broad in vitro spectrum of inhibitory properties.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 156364      PMCID: PMC383524          DOI: 10.1073/pnas.76.4.2013

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.

Authors:  V H DONALDSON; R R EVANS
Journal:  Am J Med       Date:  1963-07       Impact factor: 4.965

2.  INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.

Authors:  O EGEBERG
Journal:  Thromb Diath Haemorrh       Date:  1965-06-15

3.  Inhibition of proteases in coagulation, kinin-forming and complement systems by alpha2-plasmin inhibitor.

Authors:  M Moroi; N Aoki
Journal:  J Biochem       Date:  1977-10       Impact factor: 3.387

4.  On the interaction of alpha2-plasmin inhibitor and proteases. Evidence for the formation of a covalent crosslinkage and non-covalent weak bondings between the inhibitor and proteases.

Authors:  M Moroi; N Aoki
Journal:  Biochim Biophys Acta       Date:  1977-06-10

5.  The primary inhibitor of plasmin in human plasma.

Authors:  S Müllertz; I Clemmensen
Journal:  Biochem J       Date:  1976-12-01       Impact factor: 3.857

6.  Alteration of factor VII activity by activated Fletcher factor (a plasma kallikrein): a potential link between the intrinsic and extrinsic blood-clotting systems.

Authors:  H Saito; O D Ratnoff
Journal:  J Lab Clin Med       Date:  1975-03

7.  Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.

Authors:  R C Wiggins; B N Bouma; C G Cochrane; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

8.  Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.

Authors:  D Collen
Journal:  Eur J Biochem       Date:  1976-10-01

9.  Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

Authors:  M Moroi; N Aoki
Journal:  J Biol Chem       Date:  1976-10-10       Impact factor: 5.157

10.  The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

Authors:  O D Ratnoff; J Pensky; D Ogston; G B Naff
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

View more
  11 in total

1.  Mechanisms and specificity of factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic trypsin inhibitor.

Authors:  Duraiswamy Navaneetham; Dipali Sinha; Peter N Walsh
Journal:  J Biochem       Date:  2010-07-20       Impact factor: 3.387

2.  Inactivation of various proteinase inhibitors and the complement system in human plasma by the 56-kilodalton proteinase from Serratia marcescens.

Authors:  A Molla; T Akaike; H Maeda
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

3.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

4.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

5.  Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.

Authors:  M Schapira; C F Scott; R W Colman
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

6.  Inactivation of kallikrein in human plasma.

Authors:  F van der Graaf; J A Koedam; B N Bouma
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

7.  Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.

Authors:  C F Scott; M Schapira; H L James; A B Cohen; R W Colman
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

8.  P1 and P2' site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor.

Authors:  Duraiswamy Navaneetham; Wenman Wu; Hongbo Li; Dipali Sinha; Ronald F Tuma; Peter N Walsh
Journal:  J Biochem       Date:  2012-11-20       Impact factor: 3.387

9.  Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice.

Authors:  T Akaike; A Molla; M Ando; S Araki; H Maeda
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

10.  Guinea pig macroalbumin. A major inhibitor of activated Hageman factor in plasma with an alpha 2-macroglobulin-like nature.

Authors:  T Ishimatsu; T Yamamoto; K Kozono; T Kambara
Journal:  Am J Pathol       Date:  1984-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.